FDA Drug Recalls

Recalls / Class II

Class IID-0165-2025

Product

Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only, Source NDC 57237-0019-99, MFG: Rising Pharma, Inc., Allendale, NJ, Repackaged by: RemedyRepack Inc., Indiana, PA

Affected lot / code info
a) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025

Why it was recalled

CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Recalling firm

Firm
RemedyRepack Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
625 Kolter Dr Ste 4, Indiana, Pennsylvania 15701-3571

Distribution

Quantity
a) 1,564 cards, b) 799 bottles
Distribution pattern
Nationwide in the US

Timeline

Recall initiated
2024-12-02
FDA classified
2024-12-26
Posted by FDA
2025-01-01
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0165-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.